Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Mar 17:356:j1065.
doi: 10.1136/bmj.j1065.

Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study

Marc A Rodger  1   2   3 , Gregoire Le Gal  4   2   3   5 , David R Anderson  6 , Jeannot Schmidt  7 , Gilles Pernod  8 , Susan R Kahn  9 , Marc Righini  10 , Patrick Mismetti  11 , Clive Kearon  12 , Guy Meyer  13 , Antoine Elias  14 , Tim Ramsay  2   3 , Thomas L Ortel  15 , Menno V Huisman  16 , Michael J Kovacs  17 ; REVERSE II Study Investigators
Affiliations
Clinical Trial

Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study

Marc A Rodger et al. BMJ. .

Abstract

Objective To prospectively validate the HERDOO2 rule (Hyperpigmentation, Edema, or Redness in either leg; D-dimer level ≥250 μg/L; Obesity with body mass index ≥30; or Older age, ≥65 years), which states that women with none or one of the criteria can safely discontinue anticoagulants after short term treatment.Design Prospective cohort management study.Setting 44 secondary or tertiary care centres in seven countries.Participants Of 3155 consecutive eligible participants with a first unprovoked venous thromboembolism (VTE, proximal leg deep vein thrombosis or pulmonary embolism) who completed 5-12 months of short term anticoagulant treatment, 370 declined to participate, leaving 2785 enrolled participants. 2.3% were lost to follow-up.Interventions Women with none or one of the HERDOO2 criteria were classified as at low risk of recurrent VTE and discontinued anticoagulants (intervention arm), whereas anticoagulant management for high risk women (≥2 HERDOO2 criteria) and men was left to the discretion of the clinicians and patients (observation arm).Main outcome measure Recurrent symptomatic VTE (independently and blindly adjudicated) over one year of follow-up.Results Of 1213 women, 631 (51.3%) were classified as low risk and 591 discontinued oral anticoagulant treatment. In the primary analysis, 17 low risk women who discontinued anticoagulants developed recurrent VTE during 564 patient years of follow-up (3.0% per patient year, 95% confidence interval 1.8% to 4.8%). In 323 high risk women and men who discontinued anticoagulants, 25 had VTE during 309 patient years of follow-up (8.1%, 5.2% to 11.9%), whereas in 1802 high risk women and men who continued anticoagulants 28 had recurrent VTE during 1758 patient years of follow-up (1.6%, 1.1% to 2.3%).Conclusions Women with a first unprovoked VTE event and none or one of the HERDOO2 criteria have a low risk of recurrent VTE and can safely discontinue anticoagulants after completing short term treatment.Trial registration clinicaltrials.gov NCT00967304.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: the study was partially funded by bioMérieux the manufacturer of the Vidas D-Dimer (used in the current study); no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. All authors fulfilled the conditions required for authorship and the final manuscript has been seen and approved by all authors (see authorship appendix for detailed contributions).

Figures

None
Fig 1 HERDOO2 score to identify women with unprovoked venous thrombosis (VTE) at low risk of recurrent venous thrombosis. Visual guide adapted from Kahn et al
None
Fig 2 Participant flow. VTE=venous thromboembolism
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003;362:523-6. 10.1016/S0140-6736(03)14111-6 pmid:12932383. - DOI - PubMed
    1. Kearon C, Akl EA, Comerota AJ, et al. American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. Chest 2012;141(Suppl):e419S-94S.pmid:22315268. - PMC - PubMed
    1. White RH. The epidemiology of venous thromboembolism. Circulation 2003;107(Suppl 1):I4-8. 10.1161/01.CIR.0000078468.11849.66 pmid:12814979. - DOI - PubMed
    1. Agnelli G, Prandoni P, Santamaria MG, et al. Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001;345:165-9. 10.1056/NEJM200107193450302 pmid:11463010. - DOI - PubMed
    1. Rodger MA, Scarvelis D, Kahn SR, et al. Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: A multi-national cohort. Thromb Res 2016;143:152-8. 10.1016/j.thromres.2016.03.028 pmid:27086275. - DOI - PubMed

Associated data